GC–MS analysis, pharmacokinetic properties, molecular docking and dynamics simulation of bioactives from Curcumis maderaspatanus to target oral cancer
In Silico Pharmacology - 2024
Tóm tắt
Oral cancer (OC) which is the most predominant malignant epithelial neoplasm in the oral cavity, is the 8th commonest type of cancer globally. Natural products are excellent sources of functionally active compounds and essential nutrients that play an important role in cancer therapeutics. Using the structure-based virtual screening, drug-likeness, toxicity, and molecular dynamics simulation, the current study focused on the evaluation of anticancer activity of bioactive compounds from Curcumis maderaspatanus. AURKA, CDK1, and VEGFR-2 proteins which play a crucial role in the development and progression of oral cancer was selected as targets and 216 phytochemicals along with a known reference inhibitor were docked against these target proteins. Based on the docking score, it was found that phytochemicals namely 3-Benzoyl-2,4(1H,3H)-Pyrimidinedione (− 8.0 kcal/mol), 1-Cyclohexylethanol, trifluoroacetate (− 6.3 kcal/mol), and Alpha-Curcumene (− 8.9 kcal/mol) interacts with AURKA, CDK1, and VEGFR-2 with highest binding affinity. The molecular dynamics simulation demonstrated that the best docked complexes exhibited excellent structural stability in terms of RMSD, RSMF, SASA and Rg for a period of 100 ns. Altogether, our computational analysis reveals that the bioactives from C. maderaspatanus could emerge as efficacious drug candidates in oral cancer therapy.
Từ khóa
Tài liệu tham khảo
Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B et al (2015) GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1–2:19–25
Araki-Maeda H, Kawabe M, Omori Y, Yamanegi K, Yoshida K, Yoshikawa K et al (2022) Establishment of an oral squamous cell carcinoma cell line expressing vascular endothelial growth factor a and its two receptors. J Dent Sci 17:1471–1479
Bavetsias V, Large JM, Sun C, Bouloc N, Kosmopoulou M, Matteucci M et al (2010) Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J Med Chem 53:5213–5228
Chen X, Zhang F-H, Chen Q-E, Wang Y-Y, Wang Y-L, He J-C et al (2015) The clinical significance of CDK1 expression in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 20:e7-12
Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O (2019) Phytochemicals in cancer treatment: from preclinical studies to clinical practice. Front Pharmacol 10:1614
Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:1–13
Dawei H, Honggang D, Qian W (2018) AURKA contributes to the progression of oral squamous cell carcinoma (OSCC) through modulating epithelial-to-mesenchymal transition (EMT) and apoptosis via the regulation of ROS. Biochem Biophys Res Commun 507:83–90
Debasish S, Tripti S (2021) Molecular docking studies of 3-substituted 4-phenylamino coumarin derivatives as chemokine receptor inhibitor. J Adv Pharm Technol Res 14:943–948
Du R, Huang C, Liu K, Li X, Dong Z (2021) Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy. Mol Cancer 20:1–27
Eberhardt J, Santos-Martins D, Tillack AF, Forli S (2021) AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings. J Chem Inf Model 61:3891–3898
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A et al (2021) Cancer statistics for the year 2020: an overview. Int J Cancer 149:778–789
Fu H, Zhao D, Sun L, Huang Y, Ma X (2022) Identification of autophagy-related biomarker and analysis of immune infiltrates in oral carcinoma. J Clin Lab Anal 36:e24417
Ghafouri-Fard S, Khoshbakht T, Hussen BM, Dong P, Gassler N, Taheri M et al (2022) A review on the role of cyclin dependent kinases in cancers. Cancer Cell Int 22:1–69
Gupta N, Gupta R, Acharya AK, Patthi B, Goud V, Reddy S et al (2016) Changing trends in oral cancer - a global scenario. Nepal J Epidemiol 6:613–619
Islami F, Ward EM, Sung H, Cronin KA, Tangka FKL, Sherman RL et al (2021) Annual report to the nation on the status of cancer, part 1: national cancer statistics. J Natl Cancer Inst 113:1648–1669
Jain S, Dwivedi J, Jain PK, Satpathy S, Patra A (2016) Medicinal plants for treatment of cancer: a brief review. Pharmacogn J 8:87–102
Jin LJ, Lamster IB, Greenspan JS, Pitts NB, Scully C, Warnakulasuriya S (2016) Global burden of oral diseases: emerging concepts, management and interplay with systemic health. Oral Dis 22:609–619
Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9:153–166
Modi SJ, Kulkarni VM (2019) Vascular endothelial growth factor receptor (VEGFR-2)/KDR inhibitors: medicinal chemistry perspective. Med Drug Discov 2:100009
Mou PK, Yang EJ, Shi C, Ren G, Tao S, Shim JS (2021) Aurora kinase A, a synthetic lethal target for precision cancer medicine. Exp Mol Med 53:835–847
Oguro Y, Miyamoto N, Okada K, Takagi T, Iwata H, Awazu Y, Miki H, Hori A, Kamiyama K, Imamura S (2010) Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation. Bioorg Med Chem 18:7260–7273
Pogaku V, Gangarapu K, Basavoju S, Tatapudi KK, Katragadda SB (2019) Design, synthesis, molecular modelling, ADME prediction and anti-hyperglycemic evaluation of new pyrazole-triazolopyrimidine hybrids as potent α-glucosidase inhibitors. Bioorg Chem 93:103307
Prakash S, Radha, Kumar M, Kumari N, Thakur M, Rathour S et al (2021) Plant-based antioxidant extracts and compounds in the management of oral cancer. Antioxidants (Basel). https://doi.org/10.3390/antiox10091358
Rydén L, Linderholm B, Nielsen NH, Emdin S, Jönsson P-E, Landberg G (2003) Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 82:147–154
Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M (2015) PLIP: fully automated protein-ligand interaction profiler. Nucleic Acids Res 43:W443–W447
Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N et al (2006) Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 53:91–96
Shafiu S, Edache E, Sani U, Abatyough M (2017) Docking and virtual screening studies of tetraketone derivatives as tyrosine kinase (EGFR) inhibitors: a rational approach to anti-fungi drug design. 2017 [cited 6 Jul 2023]. Available: https://www.semanticscholar.org/paper/Docking-and-Virtual-Screening-Studies-of-as-Kinase-Shafiu-Edache/4fba90652c82f18eeb9b9dcde441337c0a6628cd#citing-papers
Sofi S, Mehraj U, Qayoom H, Aisha S, Almilaibary A, Alkhanani M et al (2022) Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors. Med Oncol 39:133
Sumalapao DE, Villarante NR, Agapito JD, Asaad AS, Gloriani NG (2020) Topological polar surface area, molecular weight, and rotatable bond count account for the variations in the inhibitory potency of antimycotics against Microsporum canis. J Pure Appl Microbiol 14(1):247–254
Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455–461
Wood DJ, Korolchuk S, Tatum NJ, Wang L-Z, Endicott JA, Noble MEM et al (2019) Differences in the conformational energy landscape of CDK1 and CDK2 suggest a mechanism for achieving selective CDK inhibition. Cell Chem Biol 26:121-130.e5